过敏性哮喘是一种常见病和多发病，我国有近1000万花粉过敏性哮喘患者，过敏原疫苗特异免疫治疗是目前唯一的对因治疗方法，但它的疗效还有待于进一步改善。本课题（1）从载药材料设计角度出发，以星型PLGA-b-PEG纳米共聚物为药物载体，包裹重组花粉变应原profilin蛋白和ISS-ODN制成纳米疫苗；再根据DC表面受体能特异性识别及结合末端含岩藻糖基载体的特性，在上述纳米疫苗粒上偶联靶向分子岩藻糖基，制备具免疫调节和药物定向递呈的双功能靶向纳米疫苗（2）通过靶向纳米疫苗治疗花粉哮喘小鼠模型，研究靶向纳米疫苗在体内细胞毒性、靶向效果和脱敏治疗疗效（如AHR测定、病理变化、细胞因子和特异性抗体检测等）。（3）在分子和细胞水平上研究疫苗靶向机理，验证疫苗对DC和Treg的作用并探讨其信号传导通路。该研究可望为临床哮喘等过敏性疾病过敏原特异性免疫治疗提供新方法和理论依据。

Allergic asthma is a commen disease that affects about 10 million people in China. The antigen spcefic immunotherapy is the only specific remidy for the treatment of allergic asthma currently; its therapeutic efficiency needs to be further improved. The present project plan to (1) design a PLGA-b-PEG nanometric polymer carrying the pollen allergen profilin and ISS-ODN, which is also conjugated with fucose base tail,the latter can target dendritic cells. This polymer can be designated a dual functional nanometric vaccine. (2) Using this nanometric vaccine treat experimental asthmatic mice to determine its therapeutic effect on asthma and possible side effects. (3) Investigation into the molecular mechanism by which the nanometric vaccine modulates the tolerogenic properties of dendritic cells and regulatory T cells. The expected results will contribute to understanding the pathogenesis of asthma and provides novel therapeutic remedies for asthma.